Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 169.70M | -3.76M | -7.74M | 2.52M | -24.53M |
| Total Depreciation and Amortization | 11.00K | 11.00K | 11.00K | 11.00K | 330.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1.05M | -2.73M | 764.00K | -43.00K | 5.54M |
| Change in Net Operating Assets | -178.87M | 1.80M | 1.15M | -18.24M | 5.27M |
| Cash from Operations | -8.11M | -4.68M | -5.82M | -15.75M | -13.39M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | 355.00K | 0.00 | 9.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2.20M | -1.72M | -10.02M | 15.60M | 11.35M |
| Cash from Investing | 2.20M | -1.36M | -10.02M | 15.61M | 11.35M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 11.62M | 1.64M | 844.00K | 453.00K | 2.78M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 11.62M | 1.64M | 844.00K | 453.00K | 2.78M |
| Foreign Exchange rate Adjustments | -10.00K | 1.00K | -12.00K | 21.00K | 4.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 5.70M | -4.40M | -15.00M | 336.00K | 746.00K |